<DOC>
	<DOCNO>NCT00175812</DOCNO>
	<brief_summary>Hypothesis : Differentiation induction therapy acute myelogenous leukemia ( AML ) use achieve disease control stabilize peripheral blood count patient acute myelogenous leukemia . Adult patient ( &lt; 18 year age ) include : Elderly patient ( &gt; 60 year age ) newly diagnose AML achieve standard chemotherapy , patient relapse resistant AML . Patients relapse resistant AML receive intensive chemotherapy . Treatment : Patients treat all-trans retinoic acid ( oral administration ) , valproic acid ( 7 day intravenous administration later oral administration ) theophyllamine ( 7 day intravenous administration later oral administration ) . Duration treatment least 2 month disease progression . Maximal duration treatment 2 year . Followup : Clinical evaluation , peripheral blood sample , bone marrow sample .</brief_summary>
	<brief_title>Differentiation Induction Acute Myelogenous Leukemia</brief_title>
	<detailed_description>Patients include : 1 . Elderly patient 60 year age newly diagnose acute myelogenous leukemia ( AML ) receive conventional intensive chemotherapy . 2 . Adult patient age ( &gt; 18 year age ) relapse resistant AML receive conventional intensive chemotherapy allogeneic stem cell transplantation . We plan include least 20 patient , possible 30 patient 3 year period . The first patient include November 2004 . Treatment : All-trans retinoic acid ( ATRA ) administer orally 22.5 mg/m2 twice daily 14 day , repeat every third month . Valproic acid start day 3 ATRA therapy , first week intravenous administration later oral administration . Theophyllamine start day 3 ATRA therapy , first week intravenous administration later oral administration . Duration treatment least 2 month unless side effect , disease progression overall duration treatment 2 year . Supportive therapy accord hospital general guideline . Followup : The first week treatment hospital . Later out-patient treatment regular control include clinical examination , peripheral blood parameter ( include serum valproic acid theophyllamin level ) , bone marrow sample .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<mesh_term>Theophylline</mesh_term>
	<criteria>Recently diagnose acute myelogenous leukemia ( AML ) Patients 60 year age Patients receive conventional chemotherapy Patients relapse refractory AML independent age Chronic myelogenous leukemia blast phase Intolerance study drug Serious liver disease No inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Acute myelogenous leukemia</keyword>
	<keyword>Differentiation</keyword>
	<keyword>All trans retinoic acid</keyword>
	<keyword>Valproic acid</keyword>
	<keyword>Theophyllamin</keyword>
</DOC>